LabCorp has received a new emergency authorization from the FDA for a COVID-19 test that does not require the use of chemical reagents to free the coronavirus’s RNA from a sample.
By using a heat-based process that traps and concentrates viral particles in order to coax out their genetic material for sequencing, the company can avoid relying on the extraction reagents required to perform most RT-PCR tests—products that have fallen into short supply over the course of the pandemic.
LabCorp said the high-throughput method will improve its efficiency and streamline the use of its resources while reducing testing delays linked to bottlenecks within the reagent supply chain. The company has previously received amendments to its test’s authorization to allow for the use of different extraction methods in the face of shortages.
Regeneron Trial Finds Covid-19 Therapy Improved Symptoms
A descriptive analysis of Regeneron Pharmaceuticals’ Phase I/II/III clinical trial has found that its antibody cocktail REGN-COV2 lowered viral load and the time to symptoms improvement in non-hospitalised Covid-19 patients.The therapy also demonstrated positive trends in decreasing medical visits.During the ongoing, randomised, double-blind trial, the combination of REGN-COV2 and usual standard-of-care is being compared to placebo plus standard-of-care.
Regeneron noted that trial participants were given a one-time infusion of 8g or 2.4g of REGN-COV2 or placebo.Data from the descriptive analysis is based on the findings from the initial 275 patients. The analysis evaluated anti-viral activity with the therapy and is intended to detect patients who are most likely to benefit from treatment.